Germany’s Merck Bets on AI Drug-Design Pacts, Rules Out M&A
Wall Street Journal
Merck—known as EMD Group in the U.S.— is betting on artificial-intelligence partnerships to develop new drugs, but said it won’t bring in external expertise through acquisitions.